2019. Ra-SBRT is Potential Immune Adjuvant for Innate Immune Cell Populations in Advance Stage NSCLC Patients . Journal of Analytical Oncology. 8, (Nov. 2019), 71–76. DOI:https://doi.org/10.30683/1927-7229.2019.08.10.